Etodolac
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Etodolac: From Pain/Inflammation (NSAID) to Spondyloarthropathy
One-Sentence Summary
Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with COX-2 preferential selectivity, originally used for osteoarthritis and rheumatoid arthritis. The TxGNN model predicts it may be effective for Spondyloarthropathy (among other conditions), with 0 clinical trials and 0 publications currently identified for the specific predicted indications — though class-level evidence for NSAIDs in spondyloarthropathy is well-established.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Osteoarthritis, rheumatoid arthritis, pain (NSAID) |
| Predicted New Indication | Acromesomelic dysplasia, Hunter-Thompson type (rank 1); Spondyloarthropathy (rank 7, most clinically relevant) |
| TxGNN Prediction Score | 99.97% (rank 1); 99.96% (spondyloarthropathy) |
| Evidence Level | L5 (rank 1, model prediction only); L4 (spondyloarthropathy, class-level mechanistic evidence) |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold (overall); Proceed with Guardrails (spondyloarthropathy only) |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, Etodolac is a pyranocarboxylic acid derivative NSAID that preferentially inhibits cyclooxygenase-2 (COX-2), thereby reducing prostaglandin E2 (PGE2) synthesis and its downstream pro-inflammatory effects. Its COX-2 selectivity offers a more favourable gastrointestinal safety profile compared to non-selective NSAIDs, making it suitable for chronic musculoskeletal conditions.
The TxGNN model generated five unique predicted indications for Etodolac. The top-ranked predictions (acromesomelic dysplasia Hunter-Thompson type, brachyolmia-amelogenesis imperfecta syndrome, brachyolmia) are ultra-rare genetic skeletal dysplasias caused by specific gene mutations (GDF5, TRPV4, PAPSS2, etc.). The mechanistic link between COX-2 inhibition and correction of congenital bone development defects is extremely tenuous (rated 1/5 stars). These high TxGNN scores likely reflect graph-structural proximity between skeletal/connective tissue disease nodes rather than genuine therapeutic potential.
The most clinically meaningful prediction is spondyloarthropathy (rank 7, score 99.96%). NSAIDs are established first-line therapy for spondyloarthropathies (including ankylosing spondylitis) per ASAS/EULAR guidelines. Etodolac’s COX-2 preferential inhibition directly addresses joint inflammation, pain, and morning stiffness in these patients. Historical clinical studies from the 1990s–2000s have evaluated etodolac in ankylosing spondylitis, providing class-level evidence. Myosclerosis (rank 5, score 99.97%) presents a weak but theoretically interesting connection via NF-kB-mediated fibrosis modulation, warranting further research.
Predicted Indications Summary
Since no clinical trials or literature were found for any of the specific predicted indications, the following table summarises all unique TxGNN predictions:
| Rank | Predicted Indication | TxGNN Score | Evidence Level | Mechanistic Link | Recommendation |
|---|---|---|---|---|---|
| 1 | Acromesomelic dysplasia, Hunter-Thompson type | 99.97% | L5 | Very weak (1/5) — rare genetic bone disorder; NSAID cannot correct GDF5 mutations | Hold |
| 3 | Brachyolmia-amelogenesis imperfecta syndrome | 99.97% | L5 | Very weak (1/5) — rare genetic disorder of bone and enamel development | Hold |
| 5 | Myosclerosis | 99.97% | L5 | Weak (2/5) — theoretical NF-kB/fibrosis link; no preclinical evidence | Research Question |
| 7 | Spondyloarthropathy, susceptibility to | 99.96% | L4 | Strong (4/5) — NSAIDs are first-line for spondyloarthropathy (ASAS/EULAR) | Proceed with Guardrails |
| 9 | Brachyolmia | 99.96% | L5 | Very weak (1/5) — overlaps with rank 3; likely redundant graph prediction | Hold |
Clinical Trial Evidence
Currently no related clinical trials registered for Etodolac in any of the specific predicted indications.
Note: While no trials were identified for the exact disease terms queried, class-level evidence exists for NSAIDs (including etodolac) in spondyloarthropathies. A broader search using terms such as “ankylosing spondylitis” or “axial spondyloarthritis” combined with “etodolac” would likely yield relevant results.
Literature Evidence
Currently no related literature available for Etodolac in any of the specific predicted indications.
Note: As with clinical trials, published studies on etodolac in ankylosing spondylitis and related spondyloarthropathies do exist in the broader literature but were not captured by the disease-specific query terms used.
Denmark Market Information
Etodolac is currently not marketed in Denmark. No marketing authorisations (neither national Laegemiddelstyrelsen nor centralised EMA) were identified.
Note: Etodolac has been marketed in other countries (e.g., USA as Lodine; Japan; India) but does not currently hold a valid marketing authorisation in Denmark. Any repurposing consideration would first require regulatory pathway assessment for market access.
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
As Etodolac is not marketed in Denmark, the SmPC from a reference country (e.g., FDA label for Lodine) should be consulted. Key safety concerns common to all NSAIDs include:
- Cardiovascular thrombotic events
- Gastrointestinal bleeding, ulceration, and perforation
- Renal toxicity
- Hepatotoxicity
- Serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis)
Conclusion and Next Steps
Decision: Hold (overall); Proceed with Guardrails (spondyloarthropathy only)
Rationale: The majority of TxGNN predictions (4 out of 5 unique indications) target ultra-rare genetic skeletal disorders for which an NSAID mechanism offers no plausible therapeutic benefit — these are rated “Hold.” The spondyloarthropathy prediction, while ranked 7th by TxGNN score, is the only clinically actionable candidate, supported by strong class-level mechanistic evidence and established guidelines. However, since Etodolac is not marketed in Denmark and no indication-specific trials were identified, further steps are needed before advancement.
To proceed, the following is needed:
- Detailed mechanism of action data for Etodolac (DrugBank API query to resolve data gap DG002)
- SmPC safety data retrieval from a reference regulatory authority (to resolve data gap DG001)
- Broader literature search for etodolac in ankylosing spondylitis/axial spondyloarthritis (using expanded search terms)
- Regulatory pathway assessment for market access in Denmark (import/compassionate use/clinical trial)
- Drug-drug interaction profiling (current DDI data returned no results)
- For the myosclerosis prediction: preclinical feasibility review of NSAID anti-fibrotic effects before any further consideration
This report was generated on 2026-04-05 based on Evidence Pack v4 (data cutoff: 2026-04-05). Results are for research purposes only and do not constitute medical advice. All drug repurposing candidates require clinical validation before application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.